Adults¹
Oral: 500 mg once daily for 3 days, or an alternative of 500 mg on Day 1, then 250 mg daily on Days 2-5
IV: 500 mg as a single dose by the IV route for at least 2 days, followed by a single daily oral dose of 500 mg to complete a 7- to 10-day course of therapy  

Pediatrics¹
10 mg/kg once daily for 3 days, or an alternative of 10 mg/kg on Day 1, then 5 mg/kg on Days 2-5

Bacteria are the most common etiological pathogens of community-acquired pneumonia (CAP) and have traditionally been divided into two groups, designated ‘typical’ and ‘atypical’²

• The most common ‘typical’ pathogens include Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, group A streptococci, and Moraxella catarrhalis²
• The most common ‘atypical’ pathogens include Legionella spp., Mycoplasma pneumoniae, and Chlamydophila pneumoniae²

Patients with chronic obstructive pulmonary disease (COPD) are at increased risk of CAP caused by H. influenzae and M. catarrhalis³

Data from the 2019 Global Burden of Disease (GBD) study showed that lower respiratory tract infections affected >480 million people globally^4,5

Lower respiratory tract infections were responsible for almost 2.5 million deaths in 2019, making this the leading cause of infectious disease mortality worldwide⁵

Pneumonia is most prevalent in South Asia and Sub-Saharan Africa⁶

Globally, pneumonia is the single largest infectious cause of death in children. In 2019, pneumonia killed more than 740,000 children under the age of 5, accounting for 14% of all deaths of children under 5 years⁶

Within Europe, CAP is the leading cause of death due to infection, with approximately 90% of deaths due to pneumonia occurring in people aged >65 years⁷

• Age (≥65 years)
• Smoking
• Alcoholism
• Immunosuppressive conditions
• Previous episode of pneumonia
• Conditions such as COPD, cardiovascular disease, cerebrovascular disease, chronic liver or renal disease, diabetes mellitus and dementia